

Lorena Lobo de Figueiredo Pontes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3419979/publications.pdf>

Version: 2024-02-01

61
papers

1,303
citations

623734

14
h-index

361022

35
g-index

66
all docs

66
docs citations

66
times ranked

2956
citing authors

#	ARTICLE	IF	CITATIONS
1	DNMT1-interacting RNAs block gene-specific DNA methylation. <i>Nature</i> , 2013, 503, 371-376.	27.8	446
2	Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1086-1090.	1.1	148
3	Treatment of Chronic Myelogenous Leukemia by Blocking Cytokine Alterations Found in Normal Stem and Progenitor Cells. <i>Cancer Cell</i> , 2015, 27, 671-681.	16.8	112
4	Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. <i>Lung Cancer</i> , 2014, 83, 37-43.	2.0	86
5	Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). <i>British Journal of Ophthalmology</i> , 2009, 93, 688-691.	3.9	79
6	Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2008, 74B, 163-168.	1.5	67
7	Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBP β expression. <i>Science Translational Medicine</i> , 2016, 8, 350ra104.	12.4	45
8	Halofuginone Has Anti-Proliferative Effects in Acute Promyelocytic Leukemia by Modulating the Transforming Growth Factor Beta Signaling Pathway. <i>PLoS ONE</i> , 2011, 6, e26713.	2.5	34
9	PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. <i>Leukemia Research</i> , 2006, 30, 1333-1339.	0.8	31
10	Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation. <i>Hematology, Transfusion and Cell Therapy</i> , 2018, 40, 120-131.	0.2	30
11	The presence of CD56/CD16 in T α cell acute lymphoblastic leukaemia correlates with the expression of cytotoxic molecules and is associated with worse response to treatment. <i>British Journal of Haematology</i> , 2009, 144, 223-229.	2.5	26
12	Methionine-induced hyperhomocysteinemia reverts fibrinolytic pathway activation in a murine model of acute promyelocytic leukemia. <i>Blood</i> , 2012, 120, 207-213.	1.4	20
13	Identification and Characterization of ALK Kinase Splicing Isoforms in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 248-253.	1.1	15
14	Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 65.	8.6	15
15	Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms. <i>Cell Death and Disease</i> , 2018, 9, 311.	6.3	14
16	The co-expression of PML/RAR alpha and AML1/ETO fusion genes is associated with ATRA resistance. <i>British Journal of Haematology</i> , 2005, 128, 407-409.	2.5	11
17	Results of FLT3 mutation screening and correlations with immunophenotyping in 169 Brazilian patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2010, 89, 225-228.	1.8	11
18	Bone Marrow Soluble Mediator Signatures of Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. <i>Frontiers in Oncology</i> , 2021, 11, 665037.	2.8	10

#	ARTICLE	IF	CITATIONS
19	Granulocyte colony-stimulating factor and leukemogenesis. <i>Mediators of Inflammation</i> , 2004, 13, 145-150.	3.0	9
20	Management of acute colorectal diseases in febrile neutropenic patients. <i>Journal of Coloproctology</i> , 2014, 34, 189-192.	0.1	8
21	NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. <i>Investigational New Drugs</i> , 2021, 39, 736-746.	2.6	7
22	The effect of intravitreal ranibizumab on intraoperative bleeding during pars plana vitrectomy for diabetic traction retinal detachment. <i>British Journal of Ophthalmology</i> , 2011, 95, 1337-1339.	3.9	6
23	C/EBP β is dispensable for steady-state and emergency granulopoiesis. <i>Haematologica</i> , 2018, 103, e331-e335.	3.5	6
24	Improved hematopoietic stem cell transplantation upon inhibition of natural killer cell-derived interferon-gamma. <i>Stem Cell Reports</i> , 2021, 16, 1999-2013.	4.8	6
25	STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. <i>Investigational New Drugs</i> , 2022, 40, 438-452.	2.6	6
26	Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 238-244.	0.2	5
27	Co-occurrence of BCR-ABL1-positive chronic myeloid leukaemia and CALR-mutated essential thrombocythaemia. <i>British Journal of Haematology</i> , 2020, 188, e21-e23.	2.5	5
28	Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia. <i>Experimental Hematology</i> , 2018, 66, 50-62.	0.4	4
29	Differential cytokine network profile in polycythemia vera and secondary polycythemia. <i>Scientific Reports</i> , 2020, 10, 7032.	3.3	4
30	Abstract 23: Sensitivity of EGFR exon 20 insertion mutations to EGFR inhibitors is determined by their location within the tyrosine kinase domain of EGFR. , 2012, , .		4
31	Decreased Activity of NK Cells in Myeloproliferative Neoplasms. <i>Blood</i> , 2015, 126, 1637-1637.	1.4	3
32	Obatoclox reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 44, 124-124.	0.2	2
33	Sensitivity to EGFR inhibitors based on location of EGFR exon 20 insertion mutations within the tyrosine kinase domain of EGFR. <i>Journal of Clinical Oncology</i> , 2012, 30, 7523-7523.	1.6	2
34	NSD1 and NSD2 Transcriptional Levels Might Predict Clinical Outcome in AML Patients. <i>Blood</i> , 2018, 132, 5257-5257.	1.4	2
35	Bioactive Lipids as Chronic Myeloid Leukemia's Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors. <i>Frontiers in Immunology</i> , 2022, 13, 840173.	4.8	2
36	Insertion (15;14)(q22;q13q32) in a case of Ph+ ALL. <i>Cancer Genetics and Cytogenetics</i> , 2008, 185, 65-67.	1.0	1

#	ARTICLE	IF	CITATIONS
37	Identification of a new translocation that disrupts the RUNX1 gene in a patient with de novo acute myeloid leukemia. <i>Medical Oncology</i> , 2012, 29, 1114-1118.	2.5	1
38	Halofuginone Exerts Antiproliferative and Antiangiogenic Actions on Acute Promyelocytic Leukemia Cells through Modulation of the TGF β Pathway. <i>Blood</i> , 2007, 110, 2850-2850.	1.4	1
39	The Use of Cyclosporine in Association with Chemotherapy As Induction Treatment in Patients with Acute Myeloid Leukemia (AML) and High Rhodamine Efflux at Diagnosis Results in Higher Complete Hematological Remission Rates, but Does Not Prolong Overall Survival. <i>Blood</i> , 2015, 126, 4896-4896.	1.4	1
40	C/Ebpg (CCAAT/Enhancer Binding Protein Gamma) Balances Cytotoxic and Secretory Potential of Natural Killer Cells. <i>Blood</i> , 2018, 132, 3721-3721.	1.4	1
41	Metformin Suppress Cellular and Molecular Processes Related to Maintenance and Proliferation of Myeloproliferative Neoplasm Stem Cell. <i>Blood</i> , 2019, 134, 1682-1682.	1.4	1
42	Suppression of multiple antiapoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. <i>Cancer Science</i> , 2021, , .	3.9	1
43	Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms. <i>Medical Oncology</i> , 2022, 39, .	2.5	1
44	Co-existence of t(6;13)(p21;q14.1) and trisomy 12 in chronic lymphocytic leukemia. <i>Medical Oncology</i> , 2012, 29, 1227-1230.	2.5	0
45	The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study. <i>Blood Advances</i> , 2017, 1, 86-89.	5.2	0
46	Feasibility of minimal residual disease studies by multiparametric flow cytometry for acute myeloid leukemia in a developing country. <i>Blood Advances</i> , 2017, 1, 80-83.	5.2	0
47	Differential Expression of P-Glycoprotein, but Not of MRP, LRP and BCRP in Leukemic Stem Cells Compared to More Differentiated CD34+ CD38+ Acute Myeloid Leukemia Blasts. <i>Blood</i> , 2006, 108, 2360-2360.	1.4	0
48	Analysis of the Crosstalk Between TGF β and VEGF-Angiogenesis in an In Vivo Model of Acute Promyelocytic Leukemia. <i>Blood</i> , 2010, 116, 1845-1845.	1.4	0
49	Flow Cytometry Quantification of Leukemic Stem Cells Is Associated with Risk Stratification and May Be Useful for Minimal Residual Disease in Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 1470-1470.	1.4	0
50	Abstract 4445: Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK translocated lung cancer. , 2013, , .		0
51	Dysregulation Of Bcl2 Family Proteins Induced By JAK2V617F Mutation Contributes To The Abnormal Expansion Of Neoplastic Initiating Cells. <i>Blood</i> , 2013, 122, 2852-2852.	1.4	0
52	Cytokine-Mediated Natural Killer Cells Effects Impair Hematopoietic Stem Cell Function. <i>Blood</i> , 2016, 128, 2641-2641.	1.4	0
53	Multitarget Antileukemic Effects of Metformin in Myeloproliferative Neoplasm Cells: Inhibition of JAK2/STAT Signaling and Mitochondrial Activity. <i>Blood</i> , 2016, 128, 1960-1960.	1.4	0
54	Nuclear SET Domain (NSD) Protein Lysine Methyltransferases (KMT) Family Members Expression in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 5097-5097.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Abnormal Distribution and Function of NK Cells Subsets May Lead to Impaired Tumor Surveillance in a JAK2V617F Myeloproliferative Neoplasm Model. <i>Blood</i> , 2018, 132, 4335-4335.	1.4	0
56	Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia. <i>Blood</i> , 2019, 134, 2719-2719.	1.4	0
57	The Scenario of Myelofibrosis in Brazil in the View of a Panel of Experts: Challenges and Proposals. <i>Blood</i> , 2019, 134, 5851-5851.	1.4	0
58	Reduced SLIT2 Are Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in APL Cells. <i>Blood</i> , 2019, 134, 5165-5165.	1.4	0
59	Efficacy of the Pan-Bcl-2 Inhibitor (Obatoclax) As a Single Agent to Treat Myeloproliferative Neoplasm in JAK2V617F Murine Transplantation Model. <i>Blood</i> , 2019, 134, 2977-2977.	1.4	0
60	Experience of Generic Imatinib As a First Line Therapy for Patients with Chronic Myeloid Leukemia in a Single Reference Institution. <i>Blood</i> , 2019, 134, 5916-5916.	1.4	0
61	Response to NK cell content does not seem to influence engraftment in ex vivo T cell depleted haploidentical stem cell transplantation. <i>Stem Cell Reports</i> , 2022, 17, 446-447.	4.8	0